A novel approach to solving the issues of diabetes shows Metadichol to be a winner.  Dr. PR Raghavan had originally published a paper for a case study for type 1 diabetes, Case Report of Type 1 Diabetes. Journal of the Science of Healing Outcomes: 2010; Vol 2(8/9):24. After five years and ending treatment the patient is still producing insulin.

  He is now to publish in the Science of Healing Outcomes in July a case report for type 2 diabetes.  Metadichol and Type 2 Diabetes Case Report (Metadichol Type2 Diabetes). From the introduction: “Globally, it is estimated that 366 million people had diabetes in 2011 (5). The number of people with type 2 diabetes is rapidly increasing in every country and in some low to middle income countries, up to 80% of people have diabetes.”  This disease ravishes the body and ultimately causes death from organ failure.  It is a disease of poor eating habits: “Type 2 diabetes is a metabolic disease that can be prevented through lifestyle modification, diet control, and control of overweight and obesity. Education of the populace is still the key to control this emerging epidemic.”

The results from the case study are amazing as the person was on no other meds, having chosen to use only Metadichol.  The figure 8 graph from the study shows a clear reduction in glucose as tested during various times throughout the day. The patient’s HbA1C was reduced from 9.8 at baseline to 6.2 at day 84.

Is Metadichol going to work for diabetics?  This is yet to be determined. This study of one person may have had significant changes in glucose because the person changed their eating and exercise habits.  Eating habits are not reported and do have a significant impact on type 2 diabetes.  However, the case study that was first reported for type 1 warrants a significant clinical trial to determine the efficacy for Metadichol for treating diabetes. Since policosanol (the primary component of Metadichol) is a food substance, this trial could be safely carried out on large populations with people that are willing to log their eating habits during the trial.

As reported in other articles on Metadichol, Dr. Raghavan believes that the effectiveness is from how nano-policosanol acts on the vitamin D receptor (VDR).  It appears to act as both an agonist and an inverse agonist which is very unusual.  In addition, Metadichol acts on many genes and other nuclear receptors as reported by Dr. Raghavan.  Will the medical community embrace a food substance for treating disease—all, yet to be determined?  – Pandemic Survivor